Welcome to our dedicated page for Prime Medicine news (Ticker: $PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prime Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prime Medicine's position in the market.
Prime Medicine, Inc. presents preclinical data showing PM359's ability to correct CGD mutation, with FDA clearance for Phase 1/2 trial. CGD is a rare disease causing severe infections. PM359 demonstrated high correction rates, restored neutrophil function, and clinical-scale production of edited cells.
Prime Medicine, Inc. (Nasdaq: PRME) will participate in the 27th Annual Milken Institute Global Conference with its CEO, Dr. Keith Gottesdiener, discussing cutting-edge technologies and scientific breakthroughs. The panel aims to offer insights into the future and will be livestreamed on May 8, 2024.
Prime Medicine, Inc. (Nasdaq: PRME) receives FDA clearance for PM359 IND application to treat Chronic Granulomatous Disease (CGD). PM359, an ex vivo product candidate utilizing Prime Editing Technology, aims to correct prevalent disease-causing mutations of CGD. Initial clinical data expected in 2025.